Moderna’s early vaccine pipeline underpinned by Epstein–Barr, norovirus and shingles prospects
Moderna’s COVID-19 vaccine was a blockbuster. Highly anticipated shots protecting against respiratory syncytial virus and cytomegalovirus are on deck. | Moderna gave its clearest look yet at a third wave of vaccine products during the company’s annual vaccines business review on Wednesday. Early-stage shots aimed at Epstein–Barr virus, norovirus and shingles could further solidify the biotech’s infectious disease portfolio.